Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys 3,620 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,620 shares of the firm’s stock in a transaction on Thursday, March 27th. The stock was purchased at an average price of $17.48 per share, with a total value of $63,277.60. Following the completion of the acquisition, the insider now owns 12,424,944 shares of the company’s stock, valued at approximately $217,188,021.12. This trade represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The shares were acquired at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was bought at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The stock was bought at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Stock Performance

STAA opened at $17.79 on Monday. The firm has a market cap of $877.49 million, a P/E ratio of -43.39 and a beta of 0.66. The business has a 50 day moving average price of $19.43 and a 200 day moving average price of $25.16. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68.

Institutional Trading of STAAR Surgical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Resona Asset Management Co. Ltd. acquired a new position in STAAR Surgical in the 4th quarter valued at $36,411,000. Vanguard Group Inc. boosted its holdings in STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after acquiring an additional 319,441 shares during the period. Yunqi Capital Ltd grew its position in shares of STAAR Surgical by 48.9% in the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock valued at $18,640,000 after purchasing an additional 252,113 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of STAAR Surgical by 25.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock worth $20,728,000 after purchasing an additional 171,046 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

STAA has been the topic of a number of research reports. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Jefferies Financial Group downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Mizuho cut STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Finally, Stephens reaffirmed an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.